Oakmark's AstraZeneca Bet: How the World's Top Drugmaker is Creating a Growth Opportunity

Oakmark Global Fund has added AstraZeneca (AZN) as a new position, betting on one of the world's largest biopharmaceutical companies. With a market cap of $261.12 billion, the company is seen as a high-growth opportunity due to its robust on-market portfolio and sector-leading late-stage pipeline. CEO Pascal Soriot is considered one of the industry's top executives. While AZN has gained 18.55% over the past 52 weeks, it posted a -3.75% decline in the last month. Oakmark views the addition as a value opportunity, citing concerns over U.S. regulations. Could this move represent a strategic play in the face of broader negativity in the biopharmaceutical sector?